Posted by Michael Wonder on 20 Mar 2022
U.S. Food and Drug Administration approves first LAG-3 blocking antibody combination, Opdualag (nivolumab and relatlimab-rmbw), as treatment for patients with unresectable or metastatic melanoma
18 March 2022 - Opdualag is a first in class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab.
Bristol Myers Squibb today announced that Opdualag (nivolumab and relatlimab-rmbw), a new, first in class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved by the U.S. FDA for the treatment of adult and paediatric patients 12 years of age or older with unresectable or metastatic melanoma.
